Welcome to our dedicated page for IDEAYA Biosciences SEC filings (Ticker: IDYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IDEAYA Biosciences's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IDEAYA Biosciences's regulatory disclosures and financial reporting.
IDEAYA Biosciences reported a larger net loss for the first quarter of 2026 while highlighting major progress in its oncology pipeline. The company posted a net loss of $98.5 million, compared with $83.3 million in the prior quarter, on collaboration revenue of $6.6 million.
Cash, cash equivalents and marketable securities totaled $972.9 million as of March 31, 2026, and IDEAYA reiterated cash runway guidance into 2030. Research and development expenses rose to $95.7 million, reflecting increased clinical activity, while general and administrative costs were $19.4 million.
The company reported that its Phase 2/3 registrational trial of darovasertib plus crizotinib in first-line HLA*A2-negative metastatic uveal melanoma met its primary endpoint, reducing the risk of disease progression by 58% with median progression-free survival of 6.9 months versus 3.1 months for investigator choice of therapy. IDEAYA plans a new drug application in the second half of 2026 under the FDA’s Real-Time Oncology Review program and outlined multiple additional clinical milestones across its ADC and synthetic lethality portfolio through 2026 and 2027.
IDEAYA Biosciences, Inc. is soliciting proxies for its 2026 virtual annual meeting on June 16, 2026 at 1:30 p.m. Pacific Time. Stockholders will vote to elect three Class I directors until the 2029 meeting, ratify PricewaterhouseCoopers LLP as independent auditor for 2026, and approve a non-binding advisory say-on-pay resolution.
Holders of 87,860,920 shares of common stock as of April 20, 2026 may vote online, by phone or by mail. The board recommends voting FOR all three proposals.
IDEAYA Biosciences reported strong positive Phase 2/3 data for darovasertib plus crizotinib in first-line metastatic uveal melanoma. In 313 patients, the combination cut the risk of disease progression by 58% versus investigator’s choice therapy, with a hazard ratio of 0.42 and p<0.0001.
Median progression-free survival was 6.9 months on the combination versus 3.1 months on standard regimens, and overall response rate was 37.1% versus 5.8%. Five complete responses were seen on the combination and none in the control arm. Safety was generally manageable, and IDEAYA plans to submit a U.S. NDA in the second half of 2026.
IDEAYA Biosciences entered a clinical collaboration with AstraZeneca to test IDEAYA’s investigational DLL3 TOP1 antibody-drug conjugate IDE849 together with AstraZeneca’s PD-L1 inhibitor Imfinzi in extensive-stage small cell lung cancer.
IDEAYA will sponsor the combination study, while AstraZeneca supplies Imfinzi. IDEAYA is running a multi-site global Phase 1 clinical trial of IDE849 in DLL3 upregulated solid tumors, including small cell lung cancer, neuroendocrine carcinomas, neuroendocrine tumors, and melanoma, reflecting significant unmet medical need and the potential of DLL3 as a targeted therapy approach.
Ideaya Biosciences Inc Schedule 13G/A amendment: The Vanguard Group reports 0 shares beneficially owned and 0% of the class. The filing explains that on January 12, 2026 Vanguard underwent an internal realignment and its subsidiaries will report ownership on a disaggregated basis.
The amendment states, in accordance with SEC Release No. 34-39538, that The Vanguard Group, Inc. no longer has beneficial ownership over securities held by those subsidiaries and/or business divisions. Signature is shown by Ashley Grim on March 27, 2026.
IDEAYA Biosciences director Jeffrey Stein bought more company stock in the open market. On March 2, 2026, he purchased 50,000 shares of common stock in open-market transactions at a weighted average price of $32.9578 per share, with individual trades executed between $32.743 and $33.1999.
Following this purchase, he directly owns 54,281 common shares. An additional 3,363 shares are reported as held indirectly by his son.
IDEAYA Biosciences, Inc. attracted institutional interest from Point72-affiliated entities, which reported a 2.1% beneficial stake in the company’s common stock. As of the close of business on December 31, 2025, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen jointly reported beneficial ownership of 1,844,556 shares, with shared voting and dispositive power and no sole authority over any shares.
The shares are held in an investment fund managed by Point72 Asset Management, with Cubist Systematic Strategies, LLC and Point72 (DIFC) Limited acting as sub-advisers for portions of the position. The filers certify the holdings were not acquired to change or influence control of IDEAYA, consistent with a passive Schedule 13G filing and reflecting ownership of 5 percent or less of the class.
IDEAYA Biosciences outlines its precision oncology strategy and late‑stage pipeline in its annual report. The company focuses on synthetic lethality and antibody‑drug conjugates, with nine potential first‑in‑class product candidates across four cancer focus areas.
Darovasertib, an oral PKC inhibitor for uveal melanoma, leads the pipeline with multiple Phase 2/3 and Phase 3 trials planned or underway across metastatic, neoadjuvant and adjuvant settings, supported by FDA Breakthrough Therapy, Fast Track and Orphan Drug designations. In August 2025, IDEAYA licensed darovasertib ex‑US to Servier for a $210.0 million upfront payment, up to $320.0 million in milestones and mid‑teen to low‑twenties royalties, while retaining U.S. rights.
The company is also advancing ADC/DDR combinations (including IDE849 and IDE161), MTAP‑pathway programs centered on MAT2A inhibitor IDE397, and next‑generation agents such as dual KAT6/7 inhibitor IDE574 and Werner helicase inhibitor IDE275. As of February 13, 2026, IDEAYA had 87,814,027 common shares outstanding, and its non‑affiliate equity market value was about $1.8 billion as of June 30, 2025.
IDEAYA Biosciences reported fourth-quarter and full-year 2025 results alongside a major pipeline update. Collaboration revenue reached $10.9 million for the quarter and $218.7 million for 2025, driven by its darovasertib license with Servier. Cash, cash equivalents and marketable securities were about $1.05 billion as of December 31, 2025, and are expected to fund operations into 2030.
R&D expenses were $86.6 million in the quarter and $314.7 million for the year, while net loss narrowed to $83.3 million for the quarter and $113.7 million for the year, both improving versus 2024. The company highlighted progress for darovasertib in uveal melanoma, with required progression-free-survival events reached in its Phase 2/3 trial and topline data expected around the last week of March, and plans for three Phase 3 registrational trials by the first half of 2026.
IDEAYA also advanced additional programs, including IDE849 and IDE034 in antibody-drug conjugates, IDE161, IDE397 and IDE892 in MTAP-pathway targeting, and IDE574 in next-generation therapies, while preparing for commercial readiness and assuming full control of certain programs as GSK exits a prior collaboration.